Cas no 110862-48-1 (Atorvastatin)
Atorvastatin Chemical and Physical Properties
Names and Identifiers
-
- Atorvastatin
- 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)-rel-
- 1H-PYRROLE-1-HEPTANOIC ACID
- (3S,5S)-7-[2-(4-Fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid
- Atorvastatin calciuM
- Atorvastatin(Relative)
- (rel)-Atorvastatin
- HSDB 7039
- rel-Atorvastatin
- Atorvastatin (Relative Stereo)
- ATORVASTATIN [VANDF]
- (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid
- 134523-03-8
- Tozalip
- Atorlip
- Cardyl
- (betaR,deltaR)-2-(p-Fluorophenyl)-beta,delta-dihydroxy-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-pyrrole-1-heptanoic Acid
- HMS3715L05
- C10AA05
- Atorvastatin (INN)
- NCGC00159458-02
- BRD-K69726342-001-02-6
- ATORVASTATIN [HSDB]
- NCGC00159458-03
- MRF-0000761
- Sortis (TN)
- Tox21_302417
- CCRIS 7159
- Q668093
- AKOS000281127
- (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-phenylcarbamoyl-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid
- MFCD00899261
- A806793
- C06834
- DB01076
- NCGC00159458-20
- sodium 7-[5-(4-fluorophenyl)-2-isopropyl-4-phenyl-3-(phenylcarbamoyl)-2,3-dihydropyrrol-1-yl]-3,5-dihydroxy-heptanoate
- Lipitor
- atorvastatina
- CAS-134523-00-5
- BDBM22164
- (3R,5R)-7-(3-(anilinocarbonyl)-5-(4-fluorophenyl)-4-phenyl-2-(propan-2-yl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoic acid
- (3R,5R)-7-(2-(4-Fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoic acid
- Lipilou
- (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid
- CHEMBL1487
- SR-01000872702
- (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-(propan-2-yl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid
- Atorvastatin calcium salt
- 134523-00-5
- Ator
- Lipilou; Tozalip; Torvast; Cardyl
- DTXSID8029868
- A802259
- GTPL2949
- SCHEMBL3831
- 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-, (R-(R*,R*))-
- HY-B0589
- Atorcor
- 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-, (betaR,deltaR)-
- BIDD:GT0336
- AS-35260
- (3R,5R)-7-[2-(4-Fluorophenyl)-5-isopropyl-3-phenyl-4-phenylcarbamoylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid
- Atorvastatin & Primycin
- CI 981
- (betaR,deltaR)-2-(p-Fluorophenyl)-beta,delta-dihydroxy-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrole-1-heptanoic acid
- atrovastin
- Lipinon
- CI-981
- ATORVASTATIN [MI]
- Atorvastatin [INN:BAN]
- 7-[2-(4-FLUORO-PHENYL)-5-ISOPROPYL-3-PHENYL-4-PHENYLCARBAMOYL-PYRROL-1-YL]- 3,5-DIHYDROXY-HEPTANOIC ACID
- atorvastatinum
- D07474
- ATORVASTATIN [WHO-DD]
- atorvastatine
- Atofast
- (3R,5R)-7-[2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid
- (R-(R*,R*))-2-(4-Fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid
- (3R,5R)-7-[3-(anilinocarbonyl)-5-(4-fluorophenyl)-4-phenyl-2-(propan-2-yl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid
- s5715
- Atorin
- 110862-48-1
- A0JWA85V8F
- Xavator
- EN300-18527331
- NS00009054
- CHEBI:39548
- ATORVASTATIN [INN]
- (.BETA.R,.DELTA.R)-2-(P-FLUOROPHENYL)-.BETA.,.DELTA.-DIHYDROXY-5-ISOPROPYL-3-PHENYL-4-(PHENYLCARBAMOYL)PYRROLE-1-HEPTANOIC ACID
- 7-(2-(4-FLUORO-PHENYL)-5-ISOPROPYL-3-PHENYL-4-PHENYLCARBAMOYL-PYRROL-1-YL)-3,5-DIHYDROXY-HEPTANOIC ACID
- 1H-PYRROLE-1-HEPTANOIC ACID, 2-(4-FLUOROPHENYL)-.BETA.,.DELTA.-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-((PHENYLAMINO)CARBONYL)-, (R-(R*,R*))-
- 7-[2-(4-FLUORO-PHENYL)-5-ISOPROPYL-3-PHENYL-4-PHENYLCARBAMOYL-PYRROL-1-YL]-3,5-DIHYDROXY-HEPTANOIC ACID
- NCGC00255181-01
- (betaR,deltaR)-2-(4-Fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic Acid
- DTXCID509868
- CCG-221172
- Lipitor(TM)
- DTXSID60274003
- Torvast
- UNII-A0JWA85V8F
- HMS3886C20
- AC-9386
- SR-01000872702-1
- Atorvastatin is known as an HMG-CoA reductase inhibitor.
- Lipitor (TN)
- (3R,5R)-7-[2-(4-FLUOROPHENYL)-3-PHENYL-4-(PHENYLCARBAMOYL)-5-PROPAN-2-YL-PYRROL-1-YL]-3,5-DIHYDROXY-HEPTANOIC ACID
- A806791
- (3R,5R)-7-[3-(anilinocarbonyl)-5-(4-fluorophenyl)-2-isopropyl-4-phenyl-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid
- XUKUURHRXDUEBC-KAYWLYCHSA-N
- rel-(3S,5S)-7-(2-(4-Fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoic acid
- BRD-K69726342-001-03-4
- GLXC-15111
- BRD-K69726342-238-02-4
-
- Inchi： 1S/C33H35FN2O5/c1-21(2)31-30(33(41)35-25-11-7-4-8-12-25)29(22-9-5-3-6-10-22)32(23-13-15-24(34)16-14-23)36(31)18-17-26(37)19-27(38)20-28(39)40/h3-16,21,26-27,37-38H,17-20H2,1-2H3,(H,35,41)(H,39,40)/t26-,27-/m1/s1
- InChI Key： XUKUURHRXDUEBC-KAYWLYCHSA-N
- SMILES： FC1C=CC(=CC=1)C1=C(C2C=CC=CC=2)C(C(NC2C=CC=CC=2)=O)=C(C(C)C)N1CC[C@H](C[C@H](CC(=O)O)O)O
Computed Properties
- Exact Mass: 558.25300
- Monoisotopic Mass: 558.253
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 8
- Hydrogen Bond Acceptor Count: 14
- Heavy Atom Count: 82
- Rotatable Bond Count: 26
- Complexity: 822
- Covalently-Bonded Unit Count: 1
- Defined Atom Stereocenter Count: 2
- Undefined Atom Stereocenter Count : 0
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- Surface Charge: 0
- Tautomer Count: 2
- XLogP3: 5
- Topological Polar Surface Area: 112
Experimental Properties
- Color/Form: No data avaiable
- Density: 1.2±0.1 g/cm3
- Melting Point: No data available
- Boiling Point: 722.2±60.0 °C at 760 mmHg
- Flash Point: 390.6±32.9 °C
- PSA: 111.79000
- LogP: 6.38660
- Vapor Pressure: 0.0±2.5 mmHg at 25°C
Atorvastatin Security Information
- Signal Word：Warning
- Hazard Statement： H315 (100%) H319 (100%) H335 (100%)
- Warning Statement： P264+P280+P305+P351+P338+P337+P313
- Safety Instruction： H315 (100%) H319 (100%) H335 (100%)
- Storage Condition：Store at 4 ° C, -4 ° C is better
Atorvastatin Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| SHANG HAI JI ZHI SHENG HUA Technology Co., Ltd. | A57140-1g |
Atorvastatin |
110862-48-1 | 95% | 1g |
￥1888.0 | 2023-09-08 | |
| SHANG HAI JI ZHI SHENG HUA Technology Co., Ltd. | A57140-100mg |
Atorvastatin |
110862-48-1 | 95% | 100mg |
￥368.0 | 2023-09-08 | |
| SHANG HAI JI ZHI SHENG HUA Technology Co., Ltd. | A57140-500mg |
Atorvastatin |
110862-48-1 | 95% | 500mg |
￥1078.0 | 2021-09-10 | |
| SHANG HAI MAI KE LIN SHENG HUA Technology Co., Ltd. | A861446-100mg |
Atorvastatin |
110862-48-1 | >98.0% | 100mg |
￥378.00 | 2022-01-13 | |
| SHANG HAI MAI KE LIN SHENG HUA Technology Co., Ltd. | A861446-500mg |
Atorvastatin |
110862-48-1 | >98.0% | 500mg |
￥1,266.00 | 2022-01-13 | |
| SHANG HAI MAI KE LIN SHENG HUA Technology Co., Ltd. | A861446-1g |
Atorvastatin |
110862-48-1 | >98.0% | 1g |
￥2,356.00 | 2022-01-13 | |
| Cooke Chemical | A1018312-1G |
Atorvastatin calcium |
110862-48-1 | 97% | 1g |
RMB 559.20 | 2025-02-21 | |
| Cooke Chemical | A1018312-5G |
Atorvastatin calcium |
110862-48-1 | 97% | 5g |
RMB 1919.20 | 2025-02-21 | |
| Cooke Chemical | A1018312-25G |
Atorvastatin calcium |
110862-48-1 | 97% | 25g |
RMB 6399.20 | 2025-02-21 | |
| 1PlusChem | 1P008RT8-100mg |
Atorvastatin |
110862-48-1 | >98.0% | 100mg |
$92.00 | 2023-12-26 |
Atorvastatin Related Literature
-
Pranav Nagarnaik,Angela Batt,Bryan Boulanger J. Environ. Monit. 2010 12 2112
Additional information on Atorvastatin
Atorvastatin (CAS No. 110862-48-1): A Comprehensive Overview
Atorvastatin (CAS No. 110862-48-1) is a widely prescribed HMG-CoA reductase inhibitor, commonly known as a statin. This compound plays a crucial role in the management of hypercholesterolemia and the prevention of cardiovascular diseases. The mechanism of action of Atorvastatin involves the inhibition of HMG-CoA reductase, the rate-limiting enzyme in the cholesterol biosynthesis pathway, leading to a significant reduction in low-density lipoprotein (LDL) cholesterol levels.
The clinical efficacy and safety profile of Atorvastatin have been extensively studied over the past few decades. Recent research has further elucidated its benefits beyond lipid lowering, including anti-inflammatory and anti-thrombotic effects. For instance, a study published in the Journal of the American College of Cardiology (JACC) in 2022 demonstrated that Atorvastatin can reduce the risk of major cardiovascular events in patients with stable coronary artery disease by up to 30%.
In addition to its primary use in lipid management, Atorvastatin has shown promise in various other therapeutic areas. Emerging evidence suggests that it may have neuroprotective properties, potentially beneficial in the treatment of neurodegenerative diseases such as Alzheimer's disease. A preclinical study published in Neuropharmacology in 2023 reported that Atorvastatin can reduce amyloid-beta plaque formation and improve cognitive function in animal models of Alzheimer's disease.
The pharmacokinetics of Atorvastatin are well-characterized. It is rapidly absorbed from the gastrointestinal tract and undergoes extensive first-pass metabolism, primarily by CYP3A4. The active metabolites contribute significantly to its therapeutic effects, with a half-life ranging from 14 to 30 hours, allowing for once-daily dosing. The drug is primarily excreted via the bile and feces, with minimal renal excretion.
Safety and tolerability are critical considerations for any medication, and Atorvastatin has an excellent safety profile when used as directed. Common side effects include myalgia, headache, and gastrointestinal disturbances, which are generally mild and transient. However, rare but serious adverse events such as rhabdomyolysis can occur, particularly when Atorvastatin is used concomitantly with certain drugs that inhibit CYP3A4 or increase plasma concentrations of statins.
To optimize the therapeutic benefits and minimize potential risks, healthcare providers should carefully consider patient-specific factors such as age, renal function, and concomitant medications when prescribing Atorvastatin. Regular monitoring of liver enzymes and muscle function is recommended, especially during the initial treatment phase or when dose adjustments are made.
The development of novel formulations and delivery systems for Atorvastatin continues to be an active area of research. For example, a recent study published in the AAPS Journal in 2023 explored the use of nanoparticle-based delivery systems to enhance the bioavailability and reduce the systemic side effects of Atorvastatin. These advancements hold promise for improving patient outcomes and expanding the therapeutic applications of this important medication.
In conclusion, Atorvastatin (CAS No. 110862-48-1) remains a cornerstone in the management of hypercholesterolemia and cardiovascular disease prevention. Its well-established efficacy, favorable safety profile, and emerging therapeutic potential make it an invaluable tool in modern medicine. Ongoing research continues to uncover new insights into its mechanisms of action and potential applications, ensuring its continued relevance and impact in clinical practice.
110862-48-1 (Atorvastatin) Related Products
- 125995-03-1(Atorvastatin lactone)
- 134395-00-9((bR,δR)-Atorvastatin tert-Butyl Ester (>90%))
- 345891-62-5(Atorvastatin Methyl Ester)
- 581772-29-4(Atorvastatin Acetonide)
- 134523-00-5(Atorvastatin)
- 433289-84-0(Desfluoroatorvastatin)
- 693794-20-6(Difluoro Atorvastatin)
- 908852-19-7(Methanamine (3R,5R)-7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoate)
- 915092-85-2(Atorvastatin Allyl Ester)
- 163217-70-7(4-Hydroxy Atorvastatin Lactone)
Audited Supplier
Audited Supplier
Audited Supplier
Audited Supplier
Audited Supplier
